Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822546 | 0.92 | ADORA1 (0.41) | ADORA1HRH3IGF1RCMKLR1 | |
| SCHEMBL6818520 | 0.91 | ADORA1 (0.40) | ADORA1HRH3IGF1RMAPK1ADORA2A | |
| SCHEMBL6822100 | 0.90 | ADORA1 (0.40) | ADORA1HRH3IGF1RCMKLR1GSK3B | |
| SCHEMBL6822058 | 0.90 | ADORA1 (0.42) | ADORA1HRH3IGF1RADORA2ACMKLR1 | |
| SCHEMBL6822090 | 0.89 | ADORA1 (0.43) | ADORA1HRH3ADORA2AFGFR1 | |
| SCHEMBL6821995 | 0.89 | ADORA1 (0.41) | ADORA1HRH3ADORA2AFGFR1 | |
| SCHEMBL6821914 | 0.88 | ADORA1 (0.41) | ADORA1HRH3ADORA2AADORA3 | |
| SCHEMBL6822608 | 0.88 | CMKLR1 (0.41) | ADORA1CMKLR1 | |
| SCHEMBL6822138 | 0.88 | ADORA1 (0.45) | ADORA1HRH3ADORA2A | |
| SCHEMBL6818702 | 0.87 | ADORA1 (0.46) | ADORA1MAPK1CMKLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | ADORA1 22/4885HRH3 275/4885IGF1R 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.